All In Biotech

Drug Trial Radar · NCT03592472

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

413

Planned (sponsor's estimate)

Start

Jul 17, 2018

Primary completion

Dec 30, 2026

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Xynomic Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Conditions

  • Renal Cell Carcinoma

Interventions

  • PazopanibDrug

    All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.

  • AbexinostatDrug

    The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

  • PlaceboOther

    The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From randomization date to date of first documentation of progression OR death (up to approximately 4 years).

Locations

38 sites in 6 countries. Site status is shown where the registry gives one.

  • University Of UA Cancer Center(UACC)/DH-SJHMC

    Phoenix, Arizona · Withdrawn

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Withdrawn

  • UCSF Helen Diller Family Comphrensive Cancer Center - Hemato

    San Francisco, California · Withdrawn

  • Norton Cancer Institute, Norton Healthcare Pavilion

    Louisville, Kentucky · Completed

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Completed

  • GU Research Network/Urology Cancer Center

    Omaha, Nebraska · Withdrawn

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Completed

  • Northwell Health/Monter Cancer Center

    Lake Success, New York · Withdrawn

  • Mainstreet Physicans Care

    Rochester, New York · Completed

  • Precision Cancer Research/Dayton Physicians Network - Treatment

    Kettering, Ohio · Withdrawn

  • Oregon Health and Science University

    Portland, Oregon · Completed

  • St. Luke's Hospital

    Easton, Pennsylvania · Completed

  • HOPE Cancer Center of East Texas

    Tyler, Texas · Completed

  • Medical Oncology Associates, PS (dba Summit Cancer Centers)

    Spokane, Washington · Withdrawn

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, China · Not yet recruiting

  • Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica

    Candiolo, Italy · Withdrawn

  • A.O. Cannizzaro_UOS Oncologia Medica

    Catania, Italy · Withdrawn

  • IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica

    Meldola (FC), Italy · Withdrawn

  • Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale

    Milan, Italy · Withdrawn

  • Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica

    Naples, Italy · Withdrawn

  • Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica

    Novara, Italy · Withdrawn

  • Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica

    Pavia, Italy · Withdrawn

  • Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria

    Pisa, Italy · Withdrawn

  • Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica

    Roma, Italy · Withdrawn

  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny

    Brzozów, Poland · Withdrawn

  • Szpitale Pomorskie Sp. z o.o. Oddział Onkologii i Radioterapii

    Gdynia, Poland · Withdrawn

  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o. Oddział Onkologii Klinicznej z Pododdziałem Dziennym

    Krakow, Poland · Completed

  • Clinical Research Center Sp. z o.o., Medic-R Sp. K.

    Poznan, Poland · Withdrawn

  • National Cancer Center - Center For Prostate Cancer

    Goyang-si, South Korea · Completed

  • CHA Bundang Medical Center, CHA University

    Seongnam-si, South Korea · Completed

  • Severance Hospital, Yonsei University Health System - Medical Oncology

    Seoul, South Korea · Completed

  • Asan Medical Center - University of Ulsan College of Medicin

    Seoul, South Korea · Completed

  • Samsung Medical Center - Hematology-Oncology

    Seoul, South Korea · Withdrawn

  • H.G.U. de Elche

    Elche, Spain · Withdrawn

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Withdrawn

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Completed

  • H.U. Virgen de la Victoria

    Málaga, Spain · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.